Zhejiang Xianju Pharmaceutical Co., Ltd. (SHE:002332)
China · Delayed Price · Currency is CNY 8.73
-0.08 (-0.91%)
Sep 10, 2026, 3:04 PM CST
SHE:002332 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 8,557 | 8,913 | 9,833 | 12,632 | 11,178 | 13,058 | |
Market Cap Growth | -21.15% | -9.36% | -22.16% | 13.01% | -14.39% | -1.20% |
Enterprise Value | 7,592 | 7,918 | 8,693 | 11,208 | 10,046 | 12,828 |
Last Close Price | 8.81 | 8.80 | 9.30 | 11.66 | 10.11 | 11.62 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 22.81 | 19.82 | 24.76 | 22.43 | 14.92 | 21.08 |
Forward PE | 18.55 | 14.65 | 12.86 | 17.64 | 14.26 | 16.42 |
PS Ratio | 2.22 | 2.37 | 2.46 | 3.06 | 2.55 | 3.00 |
PB Ratio | 1.42 | 1.47 | 1.67 | 2.17 | 2.03 | 2.64 |
P/TBV Ratio | 1.64 | 1.70 | 1.92 | 2.52 | 2.38 | 3.19 |
P/FCF Ratio | 18.94 | 232.08 | 51.46 | 35.01 | 34.21 | 31.90 |
P/OCF Ratio | 14.08 | 36.01 | 24.67 | 21.21 | 18.35 | 19.85 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 1.97 | 2.11 | 2.17 | 2.72 | 2.29 | 2.94 |
EV/EBITDA Ratio | 11.69 | 12.31 | 10.38 | 13.73 | 11.60 | 14.97 |
EV/EBIT Ratio | 17.51 | 18.46 | 14.08 | 18.53 | 14.80 | 19.06 |
EV/FCF Ratio | 16.81 | 206.17 | 45.50 | 31.06 | 30.75 | 31.34 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.03 | 0.03 | 0.01 | 0.04 | 0.06 | 0.15 |
Debt / EBITDA Ratio | 0.24 | 0.31 | 0.07 | 0.27 | 0.40 | 0.86 |
Debt / FCF Ratio | 0.35 | 5.24 | 0.31 | 0.61 | 1.05 | 1.81 |
Net Debt / Equity Ratio | -0.17 | -0.16 | -0.22 | -0.25 | -0.25 | -0.21 |
Net Debt / EBITDA Ratio | -1.57 | -1.55 | -1.58 | -1.76 | -1.59 | -1.20 |
Net Debt / FCF Ratio | -2.23 | -25.90 | -6.92 | -3.99 | -4.21 | -2.51 |
Asset Turnover | 0.54 | 0.53 | 0.57 | 0.60 | 0.65 | 0.64 |
Inventory Turnover | 1.67 | 1.62 | 1.88 | 2.17 | 2.07 | 2.26 |
Quick Ratio | 2.58 | 2.23 | 2.94 | 2.29 | 2.58 | 1.83 |
Current Ratio | 3.67 | 3.15 | 4.20 | 3.25 | 3.54 | 2.57 |
Return on Equity (ROE) | 6.66% | 7.56% | 6.83% | 9.92% | 14.29% | 13.04% |
Return on Assets (ROA) | 3.78% | 3.76% | 5.52% | 5.51% | 6.30% | 6.20% |
Return on Invested Capital (ROIC) | 7.17% | 7.51% | 11.07% | 12.44% | 14.45% | 14.79% |
Return on Capital Employed (ROCE) | 7.00% | 6.90% | 9.90% | 10.20% | 11.80% | 12.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 4.51% | 5.04% | 4.04% | 4.46% | 6.70% | 4.74% |
FCF Yield | 5.28% | 0.43% | 1.94% | 2.86% | 2.92% | 3.14% |
Dividend Yield | 4.59% | 3.41% | 3.23% | 2.57% | 2.97% | 1.29% |
Payout Ratio | 78.39% | 89.30% | 75.08% | 53.24% | 20.58% | 27.79% |
Buyback Yield / Dilution | -0.63% | -0.63% | -0.51% | 0.13% | -0.00% | -7.84% |
Total Shareholder Return | 3.96% | 2.78% | 2.71% | 2.71% | 2.97% | -6.55% |